Fwd: Recommended articles

[Okechukwu Ogah]

Dr O.S Ogah. MBBS, MSc, PhD, MD, FWACP, FACP, FESC, FNCS

A. Senior Lecturer

Cardiology Unit, Department of Medicine,

Faculty of Clinical Sciences

College of Medicine,

University of Ibadan, NIGERIA

B. Honorary Consultant Physician/Cardiologist,

Cardiology Unit,

Department of Medicine

University College Hospital Ibadan, NIGERIA

PERSONAL POSTAL ADDRESS

P.O BOX 14343, UNIVERSITY OF IBADAN  POST OFFICE

IBADAN, NIGERIA

Tel. +234 806 77 47 121
Fax. +1215-975-6817 (Electronic)
Emails: 

oso...@com.ui.edu.ng ,

osoga...@gmail.com

osoga...@yahoo.com

https://www.researchgate.net/profile/Okechukwu_Ogah4/contributions

C. Bernard Lown Visiting Scholar in Cardiovascular Health

Department of Global Health and Population

Harvard T.H. Chan School of Public Health

Email: oo...@hsph.harvard.edu

D. Adjunct Researcher,

Institute of Advanced Medical Research and Training (IAMRAT)

College of Medicine, University of Ibadan, NIGERIA

E. Affiliate Member,

The Hatter Institute for Cardiovascular Research in Africa (HICRA)

4th Floor Chris Barnard Building
Faculty of Health Sciences
University of Cape Town
Private Bag X3 7935
Observatory, SOUTH AFRICA

http://www.hatter.uct.ac.za/icra/about/staff/visiting-researchers

F. Past President,

Nigerian Cardiac Society

--------------------------------------------------------------------------------------------------------------------------------------------------

"For with thee is the fountain of life: in thy light shall we see light." Psalm 36:9

-------------------------------------------------------------------------------------------------

---------- Forwarded message ---------
From: Google Scholar Alerts <scholarale...@google.com>
Date: Sun, Dec 29, 2024 at 4:17 AM
Subject: Recommended articles
To: <osoga...@gmail.com>

[PDF] Cardiovascular and Metabolic Effects of Modulating Circulating Ketone Bodies With 1, 3‐Butanediol in Patients With Heart Failure With Reduced Ejection Fraction

H Guldbrandsen, N Gopalasingam, KH Christensen… - Journal of the American …, 2024

Background Oral treatment with the exogenous ketone body 3‐hydroxybutyrate
improves cardiac function in patients with heart failure with reduced ejection fraction,
but ketosis is limited to 3 to 4 hours. Treatment with (R)‐1, 3‐butanediol (BD) …

[PDF] Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ES Nordén, BA Bendiksen, KK Bergo, EKS Espe… - ESC Heart Failure, 2024

Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The
effect of Sac/Val on regional dysfunction following myocardial infarction (MI) remains
uncertain. This study aimed at understanding the effects of Sac/Val on regional …

[HTML] Association of Epicardial Adipose Tissue and Ventricular Arrhythmias in Patients With Nonischemic Cardiomyopathy

S Nakamori, F Yazdanian, F Ghanbari, J Rodriguez… - JACC: Advances, 2024

Background Risk stratification for sudden cardiac death (SCD) in patients with
nonischemic cardiomyopathy (NICM) remains challenging. Objectives This study
aimed to investigate the impact of epicardial adipose tissue (EAT) on SCD in NICM …

See all recommendations

 

This message was sent by Google Scholar because you're following new recommended articles for your profile.

List alerts

Cancel alert

[Okechukwu Ogah]

Neurohormonal and Renal Effects of 14-Day Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction

K Berg-Hansen, N Gopalasingam, KH Christensen… - Circulation: Heart Failure, 2024

Following 14-day treatment with KE treatment, plasma renin (P= 0.002) and
aldosterone (P= 0.030) were higher compared with placebo (Figure). Copeptin levels
did not differ significantly (P= 0.08). Lower mean arterial pressure at screening …

[PDF] Bentall Procedure in a Marfan Syndrome Patient With Reduced Ejection Fraction: A Case Report

GFB Saeed, MF Alshammari, DS Abalkhail… - Cureus, 2024

Marfan syndrome (MFS) is an autosomal dominant disorder affecting the connective
tissue, often leading to aortic root dilation, aneurysm, and dissection. We report on a
35-year-old Bangladeshi female patient with MFS who presented with chest pain …

[Okechukwu Ogah]

[PDF] Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ES Nordén, BA Bendiksen, KK Bergo, EKS Espe… - ESC Heart Failure, 2024

Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The
effect of Sac/Val on regional dysfunction following myocardial infarction (MI) remains
uncertain. This study aimed at understanding the effects of Sac/Val on regional …

[HTML] Risk of mortality between warfarin and direct oral anticoagulants: population-based cohort studies

Z Wang, J Matthewman, J Tazare, Q Yu, KS Cheung… - BMC medicine, 2024

Direct oral anticoagulants (DOACs) have been reported to be associated with a
higher risk of mortality compared with an older alternative, warfarin using primary
care data in the United Kingdom (UK). However, other studies observed …

[PDF] Association between “Life's Essential 8” cardiovascular health and apparent treatment-resistant hypertension among US adults from the NHANES, 2005 to 2018

Z Xu, R Shen, W Hu, J Shen, X Wu, L Lv - Frontiers in Cardiovascular Medicine, 2024

Background The association between healthy lifestyle and American Heart
Association (AHA) Life's Essential 8 (LE8) score and apparent treatment-resistant
hypertension (aTRH) remains uncertain. We aimed to explore the association …

[Okechukwu Ogah]

Effect of Dapagliflozin on Cardiac Structure and Function in Patients with Heart Failure Due to Mildly Reduced Ejection Fraction

XU Mengdan, H XIANG, GAO Xiaolong, J ZHANG… - 昆明医科大学学报, 2024

Objective To investigate the effects of dapagliflozin on cardiac structure and function
in patients with heart failure due to mildly reduced ejection fraction. Methods Patients
diagnosed with heart failure due to mildly reduced ejection fraction in the outpatient …

[HTML] Effect of the use of dapagliflozin in diuresis, natriuriesis, and in ultrafiltration and peritoneal elimination of sodium in patients with refractory heart failure: DAPA-DP …

M Montomoli, C Solano Rivera, MG Rico… - Renal Replacement …, 2024

Peritoneal dialysis (PD) has emerged as an effective technique for managing
refractory heart failure (HF) in patients unresponsive to diuretics. Previous meta-
analyses have demonstrated significant reductions in hospitalization days and …

[Okechukwu Ogah]

Impact of diagnostic coding schemas on major bleeding risk assessment for oral anticoagulants in patients with atrial fibrillation using administrative claims data

HT Chien, TF Chao, R Wang, CJ Chang, SY Lin, FJ Lin - Journal of Thrombosis and …, 2024

Introduction This study evaluated how different published diagnostic coding schemas
impact the assessment of major bleeding risks associated with direct oral
anticoagulants (DOACs) and warfarin. Methods This retrospective cohort study …

[HTML] Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure

TLT Huynh, PT Pham, HD Tran, ND Tran, D Van Tran… - PeerJ, 2024

Background Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and
Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum
uric acid but few studies worldwide assessed. Objective Evaluate the effectiveness of …

[PDF] Analysis of risk factors and development of prediction model for improvement of ejection fraction in patients with ischemic cardiomyopathy after percutaneous coronary …

L Su, X Fu, Y Wang, Y Jiang, Y Fu, Q Wang, W Zhi, Y Li… - 2024

Background: There is a lack of relevant studies investigating left ventricular ejection
fraction (LVEF) improvement in patients with ischemic cardiomyopathy (ICM)
following percutaneous coronary intervention (PCI). This study aimed to investigate …

[Okechukwu Ogah]

[PDF] Comparative Analysis of Mineralocorticoid Receptor Antagonists and Renin-Angiotensin System Inhibitors/Angiotensin Receptor Neprilysin Inhibitor in Heart Failure …

CC Lee, TW David, KC Chang, TT Lin, CK Wu, LY Lin - Frontiers in Pharmacology

Figure: 3 0.78-1.02) or HHF (hazard ratio= 1.01, 95% CI: 0.94-1.09). Conversely,
RASI//ARNI use was linked to a lower risk of cardiovascular death (hazard ratio=
0.82, 95% CI: 0.71-0.94) but not HHF (hazard ratio= 0.995, 95% CI: 0.924-1.07) …

[HTML] Choosing the optimal oral anticoagulant for stroke prevention in atrial fibrillation: direct oral anticoagulants vs vitamin K antagonists

S Carlin, N Chan, A Godoy, V Bhagirath, J Hirsh… - Journal of Thrombosis and …, 2024

Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) for
stroke prevention in many patients with atrial fibrillation, but VKAs may still be
preferred in some situations. We use a case-based approach to present the evidence …

Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF

X Wang, O Vardeny, B Claggett, M Vaduganathan… - European Journal of Heart …, 2024

Aims To evaluate clinical outcomes, echocardiographic features, and the efficacy
and safety of sacubitril/valsartan compared to valsartan across age groups in the
PARAGON‐HF trial. Methods and results A total of 4796 participants≥ 50 years of …

[HTML] A Tri-Component (Glomerular, Tubular, and Metabolic) Assessment of Renal Function in Acute Heart Failure

G Iwanek, B Ponikowska, H Salah, M Fudim, M Guzik… - Journal of Clinical Medicine, 2024

Background: Despite the prevalence of impaired renal function in acute heart failure
(AHF) patients, the intricate relationship between glomerular, tubular, and metabolic
renal function remains unexplored. We aimed to investigate the co-occurrence of …

[PDF] Association between'Life's Essential 8'cardiovascular health and apparent treatmentresistant hypertension among US adults from the NHANES, 2005 to 2018

J Shen - Frontiers in Cardiovascular Medicine

The association between healthy lifestyle and American Heart Association (AHA)
Life's Essential 8 (LE8) score and apparent treatment-resistant hypertension (aTRH)

remains uncertain. We aimed to explore the association between healthy lifestyle …

[Okechukwu Ogah]

[PDF] Retrospective Analysis of Sacubitril/Valsartan vs Benazepril for Treating Heart Failure Following Acute Myocardial Infarction

L Zhao, Y Ren, D Qin, X Yang, Z Chen, N Zhang - International Journal of General …, 2024

Objective To retrospectively compare the efficacy of Sacubitril/Valsartan and
Benazepril in the treatment of heart failure in patients following acute myocardial
infarction. Methods A retrospective analysis of clinical data was conducted for 103 …

[PDF] Impact of Underdosing of Direct Oral Anticoagulants on Clinical Outcomes in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

H Kitahara, T Yamazaki, T Hiraga, S Suzuki, Y Ohno… - Circulation Journal, 2024

Background: Underdoses of direct oral anticoagulants (DOAC) are sometimes
prescribed due to bleeding risk concerns in patients with atrial fibrillation (AF). We
investigated the prevalence of DOAC underdosing and its impact on clinical …

[PDF] New Biomarkers in the Prognostic Assessment of Acute Heart Failure with Reduced Ejection Fraction: Beyond Natriuretic Peptides

M Cortés, J Lumpuy-Castillo, CS García-Talavera… - 2024

Natriuretic peptides are established biomarkers related to the prognosis of heart
failure. New biomarkers have emerged in the area of cardiovascular disease. The
prognostic value of these biomarkers in heart failure with reduced LVEF (HFrEF) is …

Impact of polyvascular disease severity on acute heart failure prognosis

MV Gatuz, R Abu-Fanne, D Abramov, MA Mamas… - Heart and Vessels, 2024

Polyvascular disease, is a prevalent comorbidity among patients with acute heart
failure (AHF). Previous research has shown that polyvascular disease is a poor
prognostic factor in patients with heart failure. However, data on the relationship …

[PDF] Left ventricular myocardial molecular profile of human diabetic ischaemic cardiomyopathy

BJ Hunter, Y Zhang, D Harney, H McEwen, YC Koay… - medRxiv, 2024

Ischaemic cardiomyopathy is the most common cause of heart failure and often
coexists with diabetes mellitus which worsens patient symptom burden and
outcomes. Yet, their combined effects are seldom investigated and are poorly …

[Okechukwu Ogah]

[PDF] Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction

P Büttner, A Augstein, M Abdellatif, A Lourenço… - ESC Heart Failure, 2024

Aims ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and
Leprfa) develop metabolic syndrome and heart failure with preserved ejection
fraction (HFpEF), making them a widely used animal model in cardiometabolic …

[PDF] The Role of Echocardiography in the Diagnosis of Left Ventricular Noncompaction: Usefulness in a Resource‐Constrained Setting

AA Folson, P Eghan, D Amenu - Clinical Case Reports, 2024

Left ventricular non compaction is a genetic cardiomyopathy with a high occurence in
individuals of African ancestry and may present in adulthood with diagnostic
challenges when there is advanced heart failure. Echocardiography and Magnetic …

[PDF] End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2 …

AA Voors, M Metra, D Postmus, BH Greenberg… - European Journal of Heart …, 2024

Aims Serelaxin is recombinant human relaxin‐2, a hormone responsible for
haemodynamic adaptations and organ protection in pregnancy. In the RELAX‐AHF
trial, serelaxin demonstrated reductions in cardiac, renal and hepatic damage. In …

[Okechukwu Ogah]

[PDF] Diagnostic value of left atrial compliance in determining heart failure with preserved ejection fraction

NE Shirokov, EI Yaroslavskaya, DV Krinochkin… - artery, 2024

Objective—To study the diagnostic value of left atrial (LA) compliance using
transthoracic echocardiogram (TTE) at rest in determining of the heart failure with
preserved ejection fraction (HFpEF) depending on the result of diastolic stress test …

[HTML] One-year mortality and re-admission rate by disease etiology in National Heart Failure Registry of India

S Harikrishnan, A Bahl, A Roy, A Mishra, J Prajapati… - Nature Communications, 2025

Survival outcomes of patients with heart failure (HF) based on their disease etiology
are not well described. Here, we provide one-year mortality outcomes of 10850
patients with HF (mean age= 59.9 years, 31% women) in India. Ischemic heart …

[Okechukwu Ogah]

[PDF] PINK1 modulates Prdx2 to reduce lipotoxicity‐induced apoptosis and attenuate cardiac dysfunction in heart failure mice with a preserved ejection fraction

H Zhang, T Xu, X Mei, Q Zhao, Q Yang, X Zeng, Z Ma… - Clinical and Translational …, 2025

Introduction Heart failure with preserved ejection fraction (HFpEF) is a complex
condition characterized by metabolic dysfunction and myocardial lipotoxicity. The
roles of PTEN‐induced kinase 1 (PINK1) and peroxiredoxin‐2 (Prdx2) in HFpEF …

[PDF] Impact of Clinical Phenogroup Diversity and Multiplicity: Impact on Mechanisms of Exercise Intolerance in Heart Failure with Preserved Ejection Fraction

MD Kathryn Larson, K Omote, MD Shunichi Doi…

Aims: We aim to clarify the extent to which cardiac and peripheral impairments to
oxygen delivery and utilization contribute to exercise intolerance and risk for adverse
events, and how this relates to diversity and multiplicity in pathophysiological traits …

[Okechukwu Ogah]

Heart Failure with Preserved Ejection Fraction

A Cannata, TA McDonagh - New England Journal of Medicine, 2025

Key Points Heart Failure with Preserved Ejection Fraction Heart failure with
preserved ejection fraction is a heterogeneous syndrome. The diagnosis of the
condition requires ruling out potential confounders such as respiratory disease …

[PDF] SAFETY AND TOLERABILITY OF ARNI (SACUBITRIL VALSARTAN) IN PATIENTS WITH CHRONIC HEART FAILURE

A Siddiqi, Z Nazneen, MF Hayat, S Shahzad, S Latif… - The Research of Medical …, 2024

Introduction: Chronic heart failure (CHF) is a major global health problem, affecting
millions of people worldwide. Despite advances in the management of CHF, it
remains a significant cause of morbidity and mortality. Objectives: The main objective …

[Okechukwu Ogah]

[HTML] Dysregulation of Nitrosylation Dynamics Promotes Nitrosative Stress and Contributes to Cardiometabolic Heart Failure with Preserved Ejection Fraction

Z Li, KB LaPenna, ND Gehred, X Yu, WHW Tang… - bioRxiv, 2024

Background Recent reports suggest increased myocardial iNOS expression leads to
excessive protein s-nitrosylation, contributing to the pathophysiology of HFpEF.
However, the relationship between NO bioavailability, dynamic regulation of protein …

Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of …

Y Jenab, P Sadeghipour, R Mohseni-Badalabadi… - 2025

Background The role of direct oral anticoagulants (DOACs) in the treatment of left
ventricular thrombus (LVT) after ST-elevation myocardial infarction (STEMI) remains
uncertain. Aims We aimed to compare the effect of rivaroxaban versus warfarin in …

[HTML] The Role of Atrial Fibrillation and Oral Anticoagulation Status in Health‐Related Quality of Life 12 Months After Ischemic Stroke or TIA

MC Olma, L Steindorf‐Sabath, S Tütüncü, C Kunze… - Brain and Behavior, 2025

Aims Atrial fibrillation (AF) accounts for about 20% of all ischemic strokes worldwide.
It is known that AF impairs health‐related quality of life (HRQOL) in the general
population, but data on HRQOL in stroke patients with newly diagnosed AF are …

[HTML] MR T2* Map to Predict Worsening Hypertension Control: A Preliminary Study

CH Liu, JH Chen, AC Westphalen, CM Chen… - Life, 2025

Blood pressure measurement is important in monitoring hypertension. However,
blood pressure does not provide much information about renal condition in treated
hypertension. This study aimed to evaluate renal oxygenation in hypertensive …

[Okechukwu Ogah]

---------- Forwarded message ---------
From: Google Scholar Alerts <scholarale...@google.com>
Date: Fri, 17 Jan 2025, 07:01
Subject: Recommended articles
To: <osoga...@gmail.com>

Advancing Heart Failure Prevention: Echocardiogram Ventricular-arterial Coupling (VAC) Signaling Early Heart Failure With Preserved Ejection Fraction (HFpEF)

C Lekavich, M Fudim, G Bloomfield, W Kraus, R Mentz - Journal of Cardiac Failure, 2025

Introduction The threat of heart failure with preserved ejection fraction (HFpEF)
continues to increase affecting more than 4 million adults in the US resulting in a
50% mortality rate within 3-5 years of diagnosis and affecting unrepresented groups …

Interlukin-16 In Heart Failure With Preserved Ejection Fraction Associated Pulmonary Hypertension

Z Cai, A Fayyaz, K Koepp, Y Wang, M Redfield - Journal of Cardiac Failure, 2025

Background Inflammation has been reported as an important mediator of pulmonary
hypertension (PH), however, the key cytokine involved in heart failure with preserved
ejection fraction associated PH (HFpEF-PH) is still unknown. Aims: We aimed to …

Characteristics Of Patients Eligible For Sacubitril Valsartan Optimization

AS Gillet, P Kohli - Journal of Cardiac Failure, 2025

Introduction Sacubitril/valsartan is an angiotensin neprilysin inhibitor (ARNI).
PARADIGM-HF showed that ARNI decreases mortality and hospitalization compared
to angiotensin-converting enzyme (ACE) inhibitors for patients with heart failure with …

A 5-year Trend Analysis Of Percutaneous Coronary Intervention Rates And The Diagnosis Of Ischemic Cardiomyopathy In Acute Heart Failure Patients

O Akinti, E Duodu, C Poluyi, S Sinclair, P Wickham… - Journal of Cardiac Failure, 2025

Background The yearly trend of percutaneous coronary intervention (PCI) in acute
heart failure (AHF) patients, often with previously undiagnosed ischemic
cardiomyopathy (ICM), is unclear. This study seeks to unveil the rates of PCI and ICM …

Comparing Outcomes Of Non-Ischemic Cardiomyopathy And Ischemic Cardiomyopathy In Patients Admitted With Sepsis: A Nationwide Analysis

A Thakkar, S Gupta, L Namburu, D Kumar, V Vedantam - Journal of Cardiac Failure, 2025

Introduction Sepsis poses a significant threat to individuals with underlying cardiac
conditions, including non-ischemic cardiomyopathy (NICM) and ischemic
cardiomyopathy (ICM). This retrospective observational study compares in-hospital …

Incidence Of Ventricular Tachycardia And Fibrillation Detected By An Insertable Cardiac Monitor In Patients With Symptomatic Heart Failure With Reduced And …

R Kahwash, M Zile, MS Khan, P Chalasani, B Bertolet… - Journal of Cardiac Failure, 2025

Introduction Subcutaneous insertable cardiac monitors (ICM) have the capability to
detect tachycardia episodes which mostly includes supraventricular tachycardias
(SVT) and occasionally ventricular tachycardia and fibrillation (VT/VF). Hypothesis …

Comparison Of Hospital Outcomes Between Ischemic Cardiomyopathy And Non Ischemic Cardiomyopathy Associated Heart Failure

J Mir, A Khalil, A Malik - Journal of Cardiac Failure, 2025

Introduction Ischemic cardiomyopathy (ICM) and Non-Ischemic Cardiomyopathy
(NICM) are the two major causes of heart failure (HF). There is scarcity of data about
the differences in hospital outcomes between ICM associated heart failure and NICM …

Differences In Left-sided Heart Parameters Between Initiation And Continuous Administration Of Angiotensin Receptor Neprilysin Inhibitors In Heart Failure Patients …

Y Orihara, S Eguchi, A Eguchi, M Pfeiffer, O Ali… - Journal of Cardiac Failure, 2025

Background Guideline-directed medical therapy (GDMT) includes an ARNI.
However, the relative importance of continuing or initiating ARNI therapy during
titration of GDMT on changes in left sided heart function are unknown. Methods Sixty …

Clinical Characteristics And Outcomes Of Patients With Heart Failure And Reduced Ejection Fraction Who Underwent Chronic Total Occlusion Percutaneous Coronary …

P Weber, D Marsy, N Manandhar-Shrestha… - Journal of Cardiac Failure, 2025

Introduction Patients with ischemic cardiomyopathy and obstructive coronary artery
disease associated with chronic total occlusion (CTO) of the coronary arteries are
considered high risk for surgical revascularization given the concomitant presence of …

Three-month Mortality Outcomes Of Patients With Acute Heart Failure According To C-reactive Protein

J Cole, M Golino, J West, E Federmann, R Markley… - Journal of Cardiac Failure, 2025

Introduction Inflammation has been identified as a major pathophysiological
contributor to acute heart failure (AHF). C-reactive protein (CRP) is an acute
inflammatory protein within the bloodstream. During AHF hospitalization, CRP is not …

[Okechukwu Ogah]

---------- Forwarded message ---------
From: Google Scholar Alerts <scholarale...@google.com>
Date: Thu, 16 Jan 2025, 06:53
Subject: Recommended articles
To: <osoga...@gmail.com>

[HTML] Efficacy of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Right Ventricular Systolic Dysfunction and Preserved LV Ejection fraction: A Randomized Clinical Trial.

R Mathur, A Baroopal, CR Chaudhary, A Hakim… - Indian Heart Journal, 2025

ABSTRACT Angiotensin Receptor Neprilysin Inhibitor (ARNI) has not shown to be
promising in Heart failure with preserved LVEF. Role of ARNI in Right ventricular
systolic dysfunction with preserved LVEF needs to be evaluated. We took 50 patients …

[HTML] Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial

E Olsen, K Jamerson, RE Schmieder, CL Søraas… - European Journal of Internal …, 2024

Background There is a paucity of data investigating the impact of antihypertensive
drug classes and blood pressure (BP) treatment targets on the incidence of end-
stage kidney disease (ESKD). In patients with high-risk hypertension aged 50–80 …

[PDF] Polygenic risk scores for atrial fibrillation and heart failure and the risk of stroke and dementia

L Rydén, NM Seidu, H Wetterberg, J Najar, M Waern… - Brain Communications, 2025

Atrial fibrillation (AF) and heart failure (HF) have both been suggested to increase
stroke and dementia risk. However, in observational studies, reversed causation and
unmeasured confounding may occur. To mitigate these issues, this study aims to …

Vascular contribution to cognitive impairment in heart failure with preserved ejection fraction: TRPV4 and KLF2 as key mediators of neurovascular dysfunction in the …

SMP Lambrichts, L van der Taelen, I Pastor… - bioRxiv, 2025

Background The development of vascular cognitive impairment (VCI) and heart
failure with preserved ejection fraction (HFpEF) are strongly associated with
comorbidities such as obesity, diabetes, hypertension, and aging. Microvascular …

Effects of dapagliflozin on serum uric acid in non-diabetic patients with heart failure

LIN Mengjiao - J Clin Cardiol, 2025

Effects of dapagliflozin on serum uric acid in non-diabetic patients with heart failure
Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}}
{{subColumn.name}} 2.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …

[Okechukwu Ogah]

---------- Forwarded message ---------
From: Google Scholar Alerts <scholarale...@google.com>
Date: Tue, Jan 21, 2025 at 4:36 AM
Subject: Recommended articles
To: <osoga...@gmail.com>

Sacubitril/valsartan attenuates inflammation and myocardial fibrosis in Takotsubo-like cardiomyopathy

J Kuang, Z Jia, TK Chong, J Chen, K Liu, X Wang, Z Li… - Journal of Molecular and …, 2025

Background Takotsubo syndrome (TTS) primarily manifests as a cardiomyopathy
induced by physical or emotional stress, remains a poorly understood condition with
no established treatments. In this study, we investigated the potential of …

[PDF] Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE‐HF

N Nouhravesh, AH Gunn, D Cyr, AF Hernandez… - European Journal of Heart …, 2025

Aims Whether prior treatment with angiotensin‐converting enzyme inhibitors (ACEi)
or angiotensin receptor blockers (ARBs) modifies efficacy and safety of
sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction …

[PDF] Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin Following an Admission for Acute Heart Failure

G Miñana, R de la Espriella, M Lorenzo-Hernández… - Cardiorenal Medicine, 2025

Abstract Introduction: Antigen carbohydrate 125 (CA125) has emerged as a proxy of
fluid overload and inflammation in acute heart failure (AHF). We aimed to evaluate
the influence of dapagliflozin on CA125 levels within the first weeks after discharge …

Three-month Mortality Outcomes Of Patients With Acute Heart Failure According To C-reactive Protein

J Cole, M Golino, J West, E Federmann, R Markley… - Journal of Cardiac Failure, 2025

Introduction Inflammation has been identified as a major pathophysiological
contributor to acute heart failure (AHF). C-reactive protein (CRP) is an acute
inflammatory protein within the bloodstream. During AHF hospitalization, CRP is not …

[Okechukwu Ogah]

[HTML] Role of Life's Essential 8 score in mediating socioeconomic status in the incidence of atrial fibrillation and heart failure: a population-based cohort study

N Wang, X Jia, Z Fan, C Yang, Y Wang, J Fan, C Zhao… - Hellenic Journal of …, 2024

Objective To assess whether the Life's Essential 8 (LE8) score mediates the
association of socioeconomic status (SES) with atrial fibrillation (AF) and heart failure
(HF). Methods A total of 236,754 participants from the UK Biobank were included …

Impact of High-Risk Pregnancy on Peripartum Left Ventricular Function

Y Komoriya, K Komamura, H Miyake, H Umeda… - Circulation Reports, 2025

Background: Predictors of the clinical characteristics of pregnant women at risk of
peripartum cardiomyopathy (PPCM) remain unclear. Methods and Results: We
enrolled 450 cases of high-risk pregnancy with any risk factor from among≥ 35 …

[PDF] A Match Made Unequal: Impact of Oral Anticoagulants on Stroke Outcomes Following Propensity Score Matching

J Seetge, B Cséke, ZN Karádi, E Bosnyák, L Szapáry - 2025

Background/Objectives: Oral anticoagulants (OACs) are commonly used for stroke
prevention in patients with atrial fibrillation (AF), but their impact on long-term
outcomes following acute ischemic stroke (AIS) remains uncertain. This study …

[Okechukwu Ogah]

[HTML] Predictors and trends of 30-day readmissions in patients with acute decompensated heart failure with preserved ejection fraction: insight from the National …

S DeAngelo, R Gajjar, G Bittar-Carlini, B Aryal… - International Journal of …, 2025

Methods The Healthcare Cost and Utilization Project National Readmission
Database (NRD) was queried between 2016–2020 to study the 30-day all-cause
hospital readmission rate, predictors, duration of hospital stay, and the overall cost of …

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation

CT Ruff, SM Patel, RP Giugliano, DA Morrow, B Hug… - New England Journal of …, 2025

Background Abelacimab is a fully human monoclonal antibody that binds to the
inactive form of factor XI and blocks its activation. The safety of abelacimab as
compared with a direct oral anticoagulant in patients with atrial fibrillation is …

[PDF] Pro‐adrenomedullin as an independent predictive biomarker for heart failure in atrial fibrillation and flutter

G Hu, X Peng, L He, Y Lai, N Liu, X Li, C Sang, J Dong… - ESC Heart Failure, 2025

Aims This study aimed to investigate potential biomarkers for predicting incident
heart failure (HF) in patients with atrial fibrillation and flutter (AF and AFL), utilizing
proteomic data from the UK Biobank Pharma Proteomics Project (UKB‐PPP) …

Assessing the applicability of the DOAC, HAS‐BLED and ORBIT risk scores in Chinese patients on non‐vitamin K antagonist oral anticoagulants

M Fan, X Yin, Y Jin, X Zheng, S Zhu - British Journal of Clinical Pharmacology

Aims The suitability of the DOAC score for assessing bleeding risk in Chinese
patients with atrial fibrillation (AF) who are receiving non‐vitamin K antagonist oral
anticoagulants (NOACs) remains unclear. We compared the DOAC score to the HAS …

[PDF] Reversal of oral anticoagulation in emergency conditions: Oral anticoagulant antidotes and reversal modalities

A Falanga, C Ambaglio, L Barcella - Blood Transfusion, 2025

Anticoagulation is the mainstay of prevention and treatment of thromboembolic
phenomena and is a life-saving therapy involving a very high number of people in
the world. However, the mechanisms by which anticoagulants provide beneficial …

The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and …

P Severino, A D'Amato, S Prosperi, MV Mariani… - Current vascular pharmacology

Purpose The management of acute heart failure (AHF) is crucial and challenging.
Regarding the use of inotropes, correct patient selection and time of administration
are of the essence. We hypothesize that the early use of Levosimendan favouring …

Utility of loop diuretics as a marker of risk in clinical trials of heart failure with preserved ejection fraction: Analysis from the Swedish Heart Failure Registry

F Chouairi, M Fudim, G Savarese, B Szabo… - European journal of heart failure

Aims It is common in heart failure (HF) trials, especially in HF with preserved (HFpEF)
and mildly reduced ejection fraction (HFmrEF), to select for increased risk of
outcomes ('enrichment'). We investigated the association between loop diuretic use …

[Okechukwu Ogah]

[HTML] Association between insulin resistance indices and outcomes in patients with heart failure with preserved ejection fraction

W Ni, R Jiang, D Xu, J Zhu, J Chen, Y Lin, H Zhou - Cardiovascular Diabetology, 2025

Insulin resistance (IR) plays a pivotal role in the interplay between metabolic
disorders and heart failure with preserved ejection fraction (HFpEF). Various non-
insulin-based indices emerge as reliable surrogate markers for assessing IR …

[HTML] Association of platelet-to-lymphocyte ratio with 1-year all-cause mortality in ICU patients with heart failure

X Hu, S Cheng, H Du, Y Yin - Scientific Reports, 2024

Abstract The Platelet-to-Lymphocyte Ratio (PLR) has emerged as a cost-effective
biomarker for systemic inflammation and adverse cardiovascular outcomes, yet its
prognostic value in critically ill patients with heart failure (HF) remains unclear …

Prospective Associations Of Cardiac And Non-cardiac Dysfunction With Risk Of Incident Heart Failure With Preserved And Reduced Ejection Fraction In Late-life: The …

FR Giugni, Y Yang, B Claggett, V Lamberson… - Journal of Cardiac Failure, 2025

Introduction Postulated differences in the pathophysiology of HFpEF compared to
HFrEF include greater contributions of non-cardiac dysfunction to HFpEF. We
evaluated the associations of physiologic measures of cardiac and several non …

Increased Left Ventricular Ejection Fraction In Patients With Heart Failure With Reduced Ejection Fraction On Baroreflex Activation Therapy

V Pham, A Gan, M Fong - Journal of Cardiac Failure, 2025

Background Along with guideline directed medical therapy (GDMT), medical devices
continue to play an important role in improved quality of life and overall symptom
relief that will grow in importance as the prevalence of heart failure continues to rise …

Effect of early initiation of empagliflozin with or without sacubitril/valsartan in a swine model of myocardial infarction

D Martínez-Falguera, J Aranyo, A Teis, G Ferrer-Curriu… - British Journal of Surgery, 2025

Introduction Empagliflozin and sacubitril/valsartan reduce cardiovascular mortality
and heart failure hospitalization rates, but the effect of early initiation of these drugs
following myocardial infarction (MI) remains unknown. Methods Twenty-four pigs with …

[HTML] Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding …

GYH Lip, R Benamouzig, AC Martin, G Pesce, G Gusto… - PloS one, 2025

Background Risk factors and comorbidities can complicate management of non-
valvular atrial fibrillation. We describe and compare real-world safety and
effectiveness of direct oral anticoagulants (DOACs; apixaban, rivaroxaban …

Three-month Mortality Outcomes Of Patients With Acute Heart Failure According To Urinary Sodium Excretion

J Cole, M Golino, J West, E Federmann, R Markley… - Journal of Cardiac Failure, 2025

Introduction During acute heart failure (AHF) hospitalization, diuretics remain a
staple for symptomatic congestion relief. Failure to excrete fluid and urinary sodium
following diuretic administration implies diuretic resistance, leading to symptomatic …

[Okechukwu Ogah]

[PDF] The Applicability of Novel Predictor of Intracranial Hemorrhage in Patients With Atrial Fibrillation in the Contemporary Real‐World Clinical Practice

N Kataoka, T Imamura - Clinical Cardiology, 2025

The Applicability of Novel Predictor of Intracranial Hemorrhage in Patients With Atrial
Fibrillation in the Contemporary Real‐World Clinical Practice - PMC Skip to main
content Here's how you know Official websites use .gov A .gov website belongs to an …

[HTML] Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding …

GYH Lip, R Benamouzig, AC Martin, G Pesce, G Gusto… - PloS one, 2025

Background Risk factors and comorbidities can complicate management of non-
valvular atrial fibrillation. We describe and compare real-world safety and
effectiveness of direct oral anticoagulants (DOACs; apixaban, rivaroxaban …

The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and …

P Severino, A D'Amato, S Prosperi, MV Mariani… - Current vascular pharmacology

Purpose The management of acute heart failure (AHF) is crucial and challenging.
Regarding the use of inotropes, correct patient selection and time of administration
are of the essence. We hypothesize that the early use of Levosimendan favouring …

[Okechukwu Ogah]

[HTML] Predictors and trends of 30-day readmissions in patients with acute decompensated heart failure with preserved ejection fraction: insight from the National …

S DeAngelo, R Gajjar, G Bittar-Carlini, B Aryal… - International Journal of …, 2025

Background and Objectives Hospital readmissions serve as a significant negative
prognostic indicator and have a considerable impact on healthcare utilization among
individuals diagnosed with heart failure with preserved ejection fraction (HFpEF). For …

[HTML] WCN25-4135 SINGLE CENTRE RANDOMISED STUDY TO EVALUATE SAFETY AND EFFICACY OF SACUBITRIL-VALSARTAN IN COMPARISON TO …

B MAULIK, A PAL, P LOHIA, T MUKHERJEE… - Kidney International Reports, 2025

STUDY DESIGN: Hospital based longitudinal, randomised active control prospective
study. The design is based on parallel randomized controlled trials with non-
inferiority. AREA OF STUDY: The study is a single centre study conducted in the …

[HTML] The Predictive Value of Circulating Gal‐3 for New Stroke Events in Paroxysmal Atrial Fibrillation Patients Despite Oral Anticoagulation Medications

Y Wang, Q Luan, Y Dong, X Zhu - Clinical Cardiology, 2025

ABSTRACT Background CHA2DS2‐VASc is used to assess the risk of stroke in
patients with atrial fibrillation (AF) and guide anticoagulant treatment decisions, but it
has limitations in accurately predicting stroke risk in individual patients. The objective …

The Combined Empagliflozin and Sacubitril/Valsartan Therapy Attenuates Isoproterenol-Induced Heart Failure in Rats: Functional, Molecular, and Structural Insights

M Muric, I Srejovic, J Novakovic, V Zivkovic, JJ Jovic… - Cardiovascular Drugs and …, 2025

Purpose The idea behind this study was to assess the effects of empagliflozin and
sacubitril/valsartan and their combination on isoproterenol-induced heart failure (HF)
and underlying molecular mechanisms. Methods HF was induced with 7-day …

PET Imaging for Cardiomyopathy Challenges Simplistic Notions of Ischemia and Viability

NP Johnson, KL Gould - Heart Failure Clinics, 2025

A patient with left ventricular (LV) systolic dysfunction has historically been
categorized as having an “ischemic” or “nonischemic” cardiomyopathy. However, our
substantial experience with PET imaging in these patients, coupled with recent …

[HTML] Clinical Outcome and Costs Based on the Degree of Vitamin K Antagonist Control for Non-Valvular Atrial Fibrillation

MR Dalmau Llorca, Z Hernández Rojas… - Journal of Clinical Medicine, 2025

Introduction and objectives: Adequate anticoagulation control with vitamin K
antagonists (VKAs) in non-valvular atrial fibrillation (NVAF) improves health
outcomes. Knowing how the economic burden depends on the degree of …

[patrick idoko]

Thank you very much sir

Patrick Idoko, MBBS, FMCP, FWACP 

Consultant Physician/Cardiologist 

Federal Medical Centre, Makurdi and

Diamond Hearts Medical Services, Makurdi

--
You received this message because you are subscribed to the Google Groups "NIGERIAN CARDIAC SOCIETY" group.
To unsubscribe from this group and stop receiving emails from it, send an email to nigerian-cardiac-s...@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/nigerian-cardiac-society/CAEseqwMw4zt8cwWarjOkZc3OXQ%3DeeGzB_kYFxecz6drNYuQB7Q%40mail.gmail.com.

[Okechukwu Ogah]

Under Pressure: The Prognostic Role of Blood Pressure in Heart Failure With Preserved Ejection Fraction

S Masi, H Dalpiaz, G Savarese - Journal of the American College of Cardiology, 2025

Hypertension is widely recognized as a major risk factor for heart failure (HF), 1 and
in particular, heart failure with preserved ejection fraction (HFpEF). Randomized
controlled trials in HFpEF consistently report a very high prevalence of hypertension …

[HTML] Inpatient versus outpatient diagnosis of heart failure across the spectrum of ejection fraction: a population cohort study

H Wang, C Gao, M Guignard-Duff, C Cole, C Hall… - Heart, 2025

Background Early heart failure (HF) diagnosis is crucial to ensure that optimal
guideline-directed medical therapy (GDMT) is administered to reduce morbidity and
mortality. Limited access to echocardiography could lead to a later diagnosis for …

[PDF] The Predictive Value of Circulating Gal‐3 for New Stroke Events in Paroxysmal Atrial Fibrillation Patients Despite Oral Anticoagulation Medications

Y Wang, Q Luan, Y Dong, X Zhu - Clinical Cardiology, 2025

ABSTRACT Background CHA2DS2‐VASc is used to assess the risk of stroke in
patients with atrial fibrillation (AF) and guide anticoagulant treatment decisions, but it
has limitations in accurately predicting stroke risk in individual patients. The objective …

[PDF] Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry)

S Paolillo, C Basile, F Marzano, D Bruzzese… - ESC Heart Failure

Abstract Aims The last released European guidelines on the management of heart
failure (HF) recommend in patients with chronic HF with reduced ejection fraction
(HFrEF) a pharmacological approach based on four fundamental drugs to be rapidly …

[Okechukwu Ogah]

Vascular remodelling in a mouse model of heart failure with preserved ejection fraction

F Sanhueza‐Olivares, F Valenzuela‐Arce… - The Journal of Physiology, 2025

Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex syndrome
characterized by symptoms of HF despite normal left ventricular function. It now
accounts for> 50% of all HF cases, with the only effective treatment (morbidity …

Contemporary Management of Patients With Chagas Cardiomyopathy in Bolivia

E Czulada, S Bercovitch, Y Alshawkani, NN Weise… - JACC: Advances, 2025

Background Chagas cardiomyopathy (CCM) is the debilitating result of a parasitic
infection that causes structural and electrical abnormalities. Yet, optimal CCM
management is challenging in the resource-poor communities where it …

Response by Shen et al to Letter Regarding Article,“Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction …

L Shen, PS Jhund, JJV McMurray - Circulation, 2025

Response by Shen et al to Letter Regarding Article, “Effect of Sacubitril/Valsartan on
Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A
Prespecified Analysis of PARAGON-HF” | Circulation Skip to main content Become a …

[Okechukwu Ogah]

[HTML] Cost-Effectiveness of Mineralocorticoid Receptor Antagonists in Ischemic and Nonischemic Heart Failure With Reduced Ejection Fraction: Perspective From a …

C Koeche, ACC Nogueira, GP da Silva Amaral… - Value in Health Regional …, 2025

Abstract Objectives Mineralocorticoid receptor antagonists (MRAs) are cornerstones
in the management of heart failure (HF) with reduced ejection fraction (HFrEF). New
MRAs with improved safety profile, such as finerenone and eplerenone, were …

Letter by Tunçez and Gürses Regarding Article,“Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A …

A Tunçez, KM Gürses - Circulation, 2025

Letter by Tunçez and Gürses Regarding Article, “Effect of Sacubitril/Valsartan on

Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A
Prespecified Analysis of PARAGON-HF” | Circulation Skip to main content Become a …

[PDF] The Predictive Value of Circulating Gal‐3 for New Stroke Events in Paroxysmal Atrial Fibrillation Patients Despite Oral Anticoagulation Medications

Y Wang, Q Luan, Y Dong, X Zhu - Clinical Cardiology, 2025

ABSTRACT Background CHA2DS2‐VASc is used to assess the risk of stroke in
patients with atrial fibrillation (AF) and guide anticoagulant treatment decisions, but it
has limitations in accurately predicting stroke risk in individual patients. The objective …

Factors involved in discontinuation or dose reduction of angiotensin receptor-neprilysin inhibitor: A retrospective analysis in 200 patients

H Inoue, K Uzu, Y Fukuyama, Y Nagasawa, K Hyogo… - Journal of Cardiology, 2025

Factors involved in discontinuation or dose reduction of angiotensin receptor-neprilysin
inhibitor: A retrospective analysis in 200 patients - ScienceDirect Skip to main contentSkip
to article Elsevier logo Journals & Books Help Search My account Sign in View PDF …

Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fraction

SR Furquim, EA Bocchi, MTS de Sousa Lira… - ESC heart failure

Background Patients with heart failure with reduced ejection fraction (HFrEF) who
achieve reverse remodelling (RR) can experience a new decrease in ejection
fraction (EF), and the predictors of sustained RR (SRR) are not completely …

[Okechukwu Ogah]

Marginal structural models to evaluate the association between adherence to direct oral anticoagulants and safety or efficacy outcomes among patients with Atrial …

A Mohan, H Chen, AA Deshmukh, M Wanat, EJ Essien… - Journal of the American …, 2025

Background Although the management of AF has improved over the years,
suboptimal adherence to direct oral anticoagulants (DOACs) is a major health
concern. Adherence and long-term persistence to DOACs declines over time …

[PDF] Does hospitalisation improve oral anticoagulant optimisation in patients with atrial fibrillation?

B Kefale, GM Peterson, C Mirkazemi, NB Dwyer… - European Journal of Clinical …, 2025

Background Hospitalisation offers an opportunity for medication review and
correction, yet it has received little attention. We aimed to evaluate oral anticoagulant
(OAC) use in patients with atrial fibrillation at hospital admission and discharge and …

Factors involved in discontinuation or dose reduction of angiotensin receptor-neprilysin inhibitor: A retrospective analysis in 200 patients

H Inoue, K Uzu, Y Fukuyama, Y Nagasawa, K Hyogo… - Journal of Cardiology, 2025

Factors involved in discontinuation or dose reduction of angiotensin receptor-neprilysin
inhibitor: A retrospective analysis in 200 patients - ScienceDirect Skip to main contentSkip
to article Elsevier logo Journals & Books Help Search My account Sign in View PDF …

Mechanisms and Prognosis of Intolerance to Angiotensin Receptor Neprilysin Inhibitors in Advanced Heart Failure: Insights from Vasodilator Challenge

G Cacioli, G Gallone, A Verde, M Ciabatti, S Pidello… - Canadian Journal of …, 2025

Background Angiotensin receptor-neprilysin inhibitors (ARNI) intolerance is common
in patients suffering advanced heart failure (AdHF) and may be associated with
worse prognosis. During right heart catheterization (RHC), afterload reduction …

The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and …

P Severino, A D'Amato, S Prosperi, MV Mariani… - Current vascular …, 2025

Purpose The management of acute heart failure (AHF) is crucial and challenging.
Regarding the use of inotropes, correct patient selection and time of administration
are of the essence. We hypothesize that the early use of Levosimendan favouring …

Abstract TP13: Effectiveness and safety of direct oral anticoagulation vs. warfarin for primary prevention of stroke and bleeding risk among patients with atrial …

V Jaiswal, N Shama, A Jaiswal, N Patel, K Rajak… - Stroke, 2025

Background: Atrial fibrillation (AF) patients carry a high risk of stroke, and treatment
related bleeding complications. Evidence for the safety and efficacy of
anticoagulation remains sparse with conflicting results. Objective: We sought to …

[HTML] The antihypertensive efficacy of a quadruple single-pill combination in patients with resistant hypertension: study protocol for a randomized, open-label, crossover trial

Y Yao, X Zhang, R Ye, S Jia, X Yang, X Chen - Trials, 2025

Background Resistant hypertension (RH) is defined as uncontrolled blood pressure
(BP) despite treatment with at least three or more antihypertensive agents.
Compelling evidence has shown that such a population has a greater risk of …

[PDF] A Match Made Unequal: Impact of Oral Anticoagulants on Stroke Outcomes Following Propensity Score Matching

J Seetge, B Cséke, ZN Karádi, E Bosnyák, L Szapáry - 2025

Background/Objectives: Oral anticoagulants (OACs) are commonly used for stroke
prevention in patients with atrial fibrillation (AF), but their impact on long-term
outcomes following acute ischemic stroke (AIS) remains uncertain. This study …

[Okechukwu Ogah]

[PDF] Training‐induced change of diastolic function in heart failure with preserved ejection fraction

AB Gevaert, EB Winzer, S Mueller, S De Schutter… - ESC Heart Failure, 2025

Aims Exercise training improves aerobic capacity (V̇O2peak) in patients with heart
failure and preserved ejection fraction (HFpEF), but underlying mechanisms remain
unclear. We aimed to evaluate whether exercise training could improve systolic and …

[HTML] Prior hospitalizations as a predictor of prognosis in heart failure with mildly reduced ejection fraction

HJ Steffen, M Behnes, A Schmitt, N Abel, F Lau… - Clinical Research in …, 2025

Objective This study aims to investigate the prognostic impact of the presence and
type of prior hospitalizations in patients with heart failure with mildly reduced ejection
fraction (HFmrEF). Background Data investigating the prognostic impact of the …

[HTML] Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure

RML Neijenhuis, M Nederend, AE van Groningen… - Open Heart, 2025

Background Short-term improvements in quality of life (QOL) have been reported in
adult congenital heart disease patients with systemic right ventricle (sRV) failure after
treatment with sacubitril/valsartan. This study aimed to evaluate the medium-term …

[HTML] Number needed to treat for net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation

R Krittayaphong, S Pumprueg, A Yindeengam… - Journal of Arrhythmia, 2025

Background Oral anticoagulants (OAC) can reduce ischemic stroke/systemic
embolism (SSE) in patients with non‐valvular atrial fibrillation (AF) while increasing
the risk of major bleeding. We aimed to analyze the number needed to treat for the …

[PDF] Plasma D-Dimer Concentrations as A Risk Factor in Patients with Acute Heart Failure

J Liu, P Li, L Song - Human Biology, 2025

Objective: The aim of this clinical study was to evaluate the risk factors associated
with Acute Heart Failure (AHF) patients, classified according to the presence of
patients-reported clinical symptoms and signs. Methods: There were 181 AHF …

[PDF] The complex relationship between arterial carbon dioxide levels and acute heart failure: implications for prognosis and management

Y Afifah, I Prasetya, S Anjarwani, AA Pashira - Heart Science Journal, 2025

Acute Heart Failure (AHF) can affect carbon dioxide levels in the body by altering the
balance between ventilation and carbon dioxide production, leading to either
hypocapnia or hypercapnia. Arterial carbon dioxide (CO2) levels are essential for …

[PDF] Predictive value of PaCO2 on mortality in patients with acute heart failure

Y Afifah, I Prasetya, SS Baskoro, S Anjarwani - Heart Science Journal, 2025

Background: Patients with AHF may experience fluctuations in carbon dioxide levels,
resulting in either hypercapnia or hypocapnia. Recent research has highlighted the
significance of the relationship between CO2 fluctuation and patient outcomes …

Abstract WP311: Prevalence and In-Hospital Outcomes Associated with Cardiomyopathy Subtypes in Patients with Acute Ischemic Stroke

K McNamara, R Peyravi, O Parikh, D Tirschwell… - Stroke, 2025

Introduction: Cardiomyopathy (CM) can occur in patients hospitalized with acute
ischemic stroke (AIS). The epidemiology of AIS and concomitant CM subtypes is not
well-described. Methods: Adult hospitalizations in the National Inpatient Sample …

[PDF] Socio‐economic status and the effect of guideline‐directed medical therapy in the STRONG‐HF study

A Damasceno, H Saidu, G Cotter, B Davison… - ESC Heart Failure, 2025

Aims Acute heart failure (AHF) impacts millions globally, with outcomes varying
based on socio‐economic status (SES). Methods SES measured by annual
household income, years of education and medical insurance coverage. Each …

[Okechukwu Ogah]

[HTML] Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A …

K Katogiannis, I Ikonomidis, D Farmakis, J Thymis… - JACC: Advances, 2025

Background In patients with bone marrow transplantation (BMT) for hematologic
malignancies, evidence for prevention of cancer therapy-related cardiac dysfunction
(CTRCD) remains limited. Objectives The authors investigated whether early …

[Okechukwu Ogah]

[HTML] Sacubitril/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs

W Wei, G Xu, J Gao, G Wang, Y Wang, C Li, J Zheng… - Cardiovascular Diabetology, 2025

The recent discovery of clinically significant data, alongside novel physiological and
pathological occurrences surrounding sacubitril/valsartan (Sac/Val) beyond its
approved indications, necessitates an urgent reevaluation of its underlying …

Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis

JP Ferreira, F Vasques-Nóvoa, CE Angermann… - European journal of heart failure

Aims Empagliflozin improves outcomes in acute heart failure (AHF). Patients with
AHF and low blood pressure (BP) have poor prognosis. Whether empagliflozin is
effective and safe in patients with AHF and low BP is currently unknown. The aim of …

[Okechukwu Ogah]

Rationale and design of the Women's Ischemia Syndrome Evaluation Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With …

T Takahashi, J Wei, AC Iribarren, M Gulati… - American Heart Journal, 2025

Background There is increasing recognition that the pathophysiology of coronary
microvascular dysfunction (CMD) plays a pivotal role in the development of heart
failure with preserved ejection fraction (HFpEF). However, the mechanisms …

[HTML] Heart failure with reduced ejection fraction developed from valvular surgery: Risk factors and therapeutic effects of sacubitril valsartan

C Yuqian, H Qinghua, L Fanyan, H Lingjin, C Xuliang… - IJC Heart & Vasculature, 2025

Objective To investigate the risk factors for heart failure developed from cardiac
valvular surgery and the efficacy of sacubitril valsartan (ARNI). Methods Clinical data
from patients with left ventricular ejection fraction (LVEF)≥ 50% who consecutively …

300.20 Sodium-Glucose Cotransporter 2 Inhibitors Use and Outcomes in Patients With Heart Failure With Preserved and Mildly Reduced Ejection Fraction

A Banga, A Mendiratta, V Bansal, D Duffee - Cardiovascular Interventions, 2025

Background SGLT2 inhibitors (SGLT2i) are a critical addition to Guideline-directed
medical therapy in patients with reduced ejection fraction (EF) heart failure (HF);
however, treatment options are limited for HF with preserved EF (HFpEF) and mildly …

[HTML] Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure

RML Neijenhuis, M Nederend, AE van Groningen… - Open Heart, 2025

Background Short-term improvements in quality of life (QOL) have been reported in
adult congenital heart disease patients with systemic right ventricle (sRV) failure after
treatment with sacubitril/valsartan. This study aimed to evaluate the medium-term …

Factors involved in discontinuation or dose reduction of angiotensin receptor-neprilysin inhibitor: A retrospective analysis in 200 patients

H Inoue, K Uzu, Y Fukuyama, Y Nagasawa, K Hyogo… - Journal of Cardiology, 2025

Factors involved in discontinuation or dose reduction of angiotensin receptor-neprilysin
inhibitor: A retrospective analysis in 200 patients - ScienceDirect Skip to main contentSkip
to article Elsevier logo Journals & Books Help Search My account Sign in View PDF …

Abstract WP311: Prevalence and In-Hospital Outcomes Associated with Cardiomyopathy Subtypes in Patients with Acute Ischemic Stroke

K McNamara, R Peyravi, O Parikh, D Tirschwell… - Stroke, 2025

Introduction: Cardiomyopathy (CM) can occur in patients hospitalized with acute
ischemic stroke (AIS). The epidemiology of AIS and concomitant CM subtypes is not
well-described. Methods: Adult hospitalizations in the National Inpatient Sample …

[Okechukwu Ogah]

[HTML] Heart failure with supranormal ejection fraction: clinical characteristics and outcomes compared to mildly reduced and preserved ejection fraction

A Segev, RTB Ishay, M Metra, E Maor, D Freimark… - Clinical Research in …, 2025

Background Little is known about the recently emerging entity, heart failure with
supranormal ejection fraction (HFsnEF). Objective To describe the clinical
characteristics and outcome of HFsnEF, compared to HF with mildly reduced EF …

Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD

MP Bonaca, SD Wiviott, TA Zelniker

[Okechukwu Ogah]

[HTML] Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose …

DJ McDonough - Physiologia, 2025

Heart failure is a leading cause of morbidity and mortality worldwide [1], and with
continued increases in the global prevalence of key disease drivers like physical
inactivity and obesity in an aging population [2–7], heart failure with preserved …

Maintained sympathetic reactivity but blunted pressor response to static handgrip exercise in heart failure with preserved ejection fraction

T Washio, R Takeda, SL Hissen, JD Akins… - Clinical Autonomic …, 2025

Purpose Recent studies have reported blunted increases in blood pressure (BP)
during static handgrip (SHG) in patients with heart failure with preserved ejection
fraction (HFpEF), which may be attributed to abnormal sympathetic reactivity during …

[PDF] Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fraction

SR Furquim, EA Bocchi, MTSS Lira, MRB Wanderley Jr… - ESC Heart Failure, 2025

Background Patients with heart failure with reduced ejection fraction (HFrEF) who
achieve reverse remodelling (RR) can experience a new decrease in ejection
fraction (EF), and the predictors of sustained RR (SRR) are not completely …

[PDF] Valsartan to Prevent Acquired Pulmonary Vein Stenosis in Pediatric Patients After Total Anomalous Pulmonary Venous Connection Surgery

J Shentu, M Zhang, Z Xu, C Wen, H Zhang, Z Zhu… - Journal of the American …, 2025

Background Recurrent pulmonary vein stenosis (PVS) following surgical repair of
total anomalous pulmonary venous connection is associated with poor prognosis.
Preclinical studies have shown that use of an angiotensin receptor blocker can …

[HTML] Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a …

R Veltkamp, E Korompoki, KH Harvey, ER Harvey… - The Lancet, 2025

Summary Background Direct oral anticoagulants (DOACs) reduce the rate of
thromboembolism in patients with atrial fibrillation but the benefits and risks in
survivors of intracerebral haemorrhage are uncertain. We aimed to determine …

[HTML] Effect of initiation with sacubitril/valsartan on blood neurodegeneration markers in HFrEF

S Prausmüller, R Wurm, M Ponleitner, E Stögmann… - Journal of Cardiac Failure, 2025

Background Sacubitril/valsartan is a key therapy for heart failure with reduced
ejection fraction (HFrEF). However, concerns remain regarding its potential impact
on cognitive function since neprilysin inhibition may influence amyloid-β (Aβ) …

[PDF] A SINGLE CENTRE, DOUBLE BLIND, RANDOMISED, ACTIVE CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SACUBITRIL/VALSARTAN IN …

B Maulik, A Pal, S Dasgupta

Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular
events and progression to end-stage renal disease (ESRD). While RAS inhibitors
slow CKD progression, significant risks remain, particularly heart failure …

Acute heart failure as a predictor of short-term cardiovascular outcomes in patients with acute ischemic stroke

Y Tateishi, K Soejima, Y Ideguchi, T Amano… - Journal of the Neurological …, 2025

Background The impact of acute heart failure following acute ischemic stroke on
short-term cardiovascular outcomes remains unclear. This study investigated the
association between acute heart failure and cardiovascular outcomes within 90 days …

Differences Between Ischemic and Non-Ischemic Cardiomyopathy in Heart Failure Related Cardiogenic Shock

J Feinman, MI Tomey, MG Palazzolo, M Martillo… - Journal of Cardiac Failure, 2025

Background Heart failure-related cardiogenic shock (HF-CS) accounts for a growing
proportion of cardiogenic shock (CS) related admissions to contemporary cardiac
intensive care units. Limited data exists comparing non-ischemic (NICM) and …

[HTML] Contemporary Management of Patients With Chagas Cardiomyopathy in Bolivia

E Czulada, S Bercovitch, Y Alshawkani, N Noya Weise… - JACC: Advances, 2025

Background Chagas cardiomyopathy (CCM) is the debilitating result of a parasitic
infection that causes structural and electrical abnormalities. Yet, optimal CCM
management is challenging in the resource-poor communities where it …

[Okechukwu Ogah]

Vascular remodelling in a mouse model of heart failure with preserved ejection fraction

F Sanhueza‐Olivares, F Valenzuela‐Arce… - The Journal of Physiology, 2025

Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex syndrome
characterized by symptoms of HF despite normal left ventricular function. It now
accounts for> 50% of all HF cases, with the only effective treatment (morbidity …

Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement …

H Skouri, N Girerd, L Monzo, MC Petrie, M Böhm… - European Journal of Heart …, 2025

Despite major advancements in heart failure (HF) management and guideline
recommendations over the past two decades, real‐world evidence highlights
suboptimal implementation of guideline‐directed medical therapy (GDMT) for HF …

Potential for improve drisk stratification by combining heart rate and systolic blood pressure in patients with acute heart failure: findings from the RICA Registry

MMP Barquero, JS Gil, L Manzano, F Formiga…

[Okechukwu Ogah]

[HTML] Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose …

DJ McDonough - Physiologia, 2025

Heart failure is a leading cause of morbidity and mortality worldwide [1], and with
continued increases in the global prevalence of key disease drivers like physical
inactivity and obesity in an aging population [2–7], heart failure with preserved …

Cerebrovascular responses to muscle metaboreflex activation in patients living with heart failure with reduced ejection fraction

TJ Jurrissen, AMS Luchkanych, NG Boyes… - Journal of Applied …, 2025

Impaired cerebrovascular control in patients with heart failure with reduced ejection
fraction (HFrEF) has been attributed to cardiac impairment and exaggerated
sympathetic-mediated cerebral vasoconstriction. The goal of this study was to …

Marginal structural models to evaluate the association between adherence to direct oral anticoagulants and safety or efficacy outcomes among patients with Atrial …

A Mohan, H Chen, AA Deshmukh, M Wanat, EJ Essien… - Journal of the American …, 2025

Background Although the management of AF has improved over the years,
suboptimal adherence to direct oral anticoagulants (DOACs) is a major health
concern. Adherence and long-term persistence to DOACs declines over time …

700.31 30-Day Ejection Fraction Changes After Transcatheter Aortic Valve Replacement: Associations With Mortality, Stroke, and Reintervention

S Mandava, K Vedantham, C Torres, N Beohar - Cardiovascular Interventions, 2025

Background Data on transcatheter aortic valve replacement (TAVR) in severe aortic
stenosis (AS) with acute heart failure (AHF) is limited and conflicting. We aimed to
examine the relationship between post-TAVR ejection fraction (EF) changes and …

Sodium-Glucose Cotransporter 2 inhibitor Empagliflozin Enhances Autophagy and Reverses Remodeling in Hearts with Large, Old Myocardial Infarctions

S Endo, H Kanamori, A Yoshida, G Naruse, S Komura… - European Journal of …, 2025

Large clinical trials recently showed that sodium-glucose cotransporter 2 (SGLT2)
inhibitors improve the prognosis of heart failure patients with or without diabetes.
Using a mouse model of large myocardial infarction, we investigated the therapeutic …

[HTML] Contemporary Management of Patients With Chagas Cardiomyopathy in Bolivia

E Czulada, S Bercovitch, Y Alshawkani, N Noya Weise… - JACC: Advances, 2025

Background Chagas cardiomyopathy (CCM) is the debilitating result of a parasitic
infection that causes structural and electrical abnormalities. Yet, optimal CCM
management is challenging in the resource-poor communities where it …

P004| Effect of nebivolol-valsartan and nebivolol-lisinopril combination therapy on IL-6 and TNF-α in hypertension

TL Orenstein, TG Parker, JW Butany, JM Goodman…